Brief: Aligos Therapeutics Reprioritizes Of Nash & Covid Programs

Aligos Therapeutics

08/02/2023 22:05

Feb 8 (Reuters) - Aligos Therapeutics Inc  ALGS.O :
    * ALIGOS THERAPEUTICS ANNOUNCES STRATEGIC REPRIORITIZATION
OF NASH
AND COVID-19 PROGRAMS AND CONFIRMS KEY TIMELINES AND EXTENSION
OF CASH RUNWAY TO YEAR-END 2024
    * ALIGOS THERAPEUTICS INC - OVERALL WORKFORCE REDUCTION
(ATTRITION
AND REDUCTION IN FORCE) OF APPROXIMATELY 25% SINCE BEGINNING OF
JANUARY 2022
    * ALIGOS THERAPEUTICS - PIPELINE REPRIORITIZATION EMPHASIZES
NASH
AND COVID-19 ASSETS, ALG-055009 AND ALG-097558
    * ALIGOS THERAPEUTICS INC - PIPELINE REPRIORITIZATION
EMPHASIZES
KEY ONGOING COLLABORATIONS, INCLUDING MERCK & CO. PROGRAMS IN
NASH
    * ALIGOS THERAPEUTICS INC - PORTFOLIO REPRIORITIZATION IS
BEING
ACCOMPANIED BY A REDUCTION OF COMPANY'S CURRENT WORKFORCE OF
APPROXIMATELY 10%
    * ALIGOS THERAPEUTICS INC - COMPANY EXPECTS TO MAINTAIN A
STRONG
BALANCE SHEET AND EXTEND ITS PROJECTED CASH RUNWAY TO END OF
2024

Source text for Eikon:  ID:nGNX4NshYj 
Further company coverage:  ALGS.O 
 ((Reuters.Briefs@thomsonreuters.com;))